On Thursday, Bath & Body Works Inc. (NYSE:BBWI) experienced a downward revision in its stock price target from a financial firm, following a report of weaker than anticipated sales in the second quarter of 2024. The firm has adjusted the price target to $40.00, a decrease from the former $55.00, while still retaining a Buy rating on the company's shares.
The revision comes after Bath & Body Works reported sales that fell short of expectations for their semi-annual sale event. Consequently, the company's management has also revised its full-year 2024 sales guidance downward, now projecting a decrease of 4% to 2%, compared to the previous forecast of a 2.5% decrease to flat growth. This update reflects an absence of growth in the second half of the year, contrary to the earlier assumption of a sales upturn during that period.
The financial firm acknowledges that the adjusted expectations could set a new baseline for potential outperformance in the latter half of the year. However, it also recognizes ongoing concerns, including weaker consumer trends that persist in the market and the potential impact of a shorter holiday season on sales performance.
Bath & Body Works' revised full-year guidance and the corresponding price target adjustment indicate a cautious outlook for the retailer's performance in the upcoming months. The company's stock price target has been adjusted in light of the recent sales data and forward-looking projections provided by the company's management.
In other recent news, Bath & Body Works reported a modest earnings per share (EPS) increase that surpassed expectations due to better margins, despite a shortfall in revenue. The company's fiscal year 2024 guidance was updated, raising the lower end while lowering the higher end of projections, due to a more cautious outlook for second-half demand.
Analyst firms Baird, BofA Securities, and JPMorgan all adjusted their outlooks on Bath & Body Works, reducing their price targets while maintaining their ratings. The company's recent financial performance and market conditions have led to a downward adjustment in forward-looking estimates, focusing on a reduced revenue forecast.
Bath & Body Works reported a 2% sales decline in Q2, prompting a downward revision of its full-year sales guidance. Despite the sales drop, the company managed to report adjusted EPS of $0.37 for the second quarter of fiscal year 2024, slightly above the consensus estimate of $0.36.
The company has raised its cost optimization savings target to $130 million from $100 million and is set to repurchase $400 million in shares. These recent developments underline Bath & Body Works' efforts to navigate a challenging market while striving for operational efficiency and growth.
InvestingPro Insights
As Bath & Body Works Inc. (NYSE:BBWI) grapples with revised sales expectations and a cautious outlook, the company's proactive strategies and market performance metrics provide a broader context for investors.
According to InvestingPro data, Bath & Body Works has a market capitalization of $7.75 billion and is trading at a low P/E ratio of 7.79, suggesting a potentially undervalued stock relative to near-term earnings growth. Additionally, with a PEG ratio of 0.22 for the last twelve months as of Q2 2025, the company shows a favorable growth-valuation balance.
InvestingPro Tips highlight the company's ongoing efforts to enhance shareholder value, with management aggressively buying back shares and maintaining a high shareholder yield. Moreover, Bath & Body Works has demonstrated a commitment to dividends, having maintained dividend payments for 52 consecutive years. These factors, combined with the prediction by analysts that the company will remain profitable this year, provide a counterbalance to the recent dip in share price.
For investors seeking more comprehensive analysis, InvestingPro offers additional tips on Bath & Body Works Inc. (https://www.investing.com/pro/BBWI), including insights on earnings revisions and stock price trends over various periods. With the next earnings date scheduled for November 13, 2024, and an InvestingPro fair value estimate of $44.26, which notably exceeds the revised analyst target, the platform offers an extensive array of data points and expert views to inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.